Published in Br J Clin Pharmacol on February 01, 1977
Studies of cardioselectivity and partial agonist activity in beta-adrenoceptor blockade comparing effects on heart rate and peak expiratory flow rate during exercise. Br J Clin Pharmacol (1978) 2.07
Erythrocyte G protein as a novel target for malarial chemotherapy. PLoS Med (2006) 1.31
Clinical pharmacology of labetalol. Br J Clin Pharmacol (1979) 1.09
Bronchial and cardiac beta-adrenoceptor blockade--a comparison of atenolol, acebutolol and labetalol. Br J Clin Pharmacol (1981) 1.06
Effect of indoramin, labetalol and alinidine on sympathetic function in normal man. Br J Clin Pharmacol (1984) 0.75
Control of heart rate by the autonomic nervous system. Studies in man on the interrelation between baroreceptor mechanisms and exercise. Circ Res (1966) 3.95
Beta-adrenoceptors in the human dorsal hand vein, and the effects of propranolol and practolol on venous sensitivity to noradrenaline. Br J Clin Pharmacol (1975) 2.94
New approach to assessment of cardioselectivity of beta-blocking drugs. Br Med J (1974) 2.06
Influence of metoprolol and propranolol on hemodynamic effects induced by adrenaline and physical work. Acta Pharmacol Toxicol (Copenh) (1975) 1.64
Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol. Br J Clin Pharmacol (1976) 1.53
Letter: Intravenous labetalol in severe hypertension. Lancet (1975) 1.37
Comparison of intravenous AH 5158 (ibidomide) and propranolol in asthma. Br Med J (1975) 1.32
Calcium ions and the regulation of NAD+-linked isocitrate dehydrogenase from the mitochondria of rat heart and other tissues. Biochem J (1978) 2.38
Pharmacologically effective plasma concentrations of ranitidine. Lancet (1979) 2.13
Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet (1994) 1.89
Pharmacological effects of labetalol in man. Br J Clin Pharmacol (1976) 1.86
Complex hormonal regulation of rat casein gene expression. J Biol Chem (1982) 1.80
Relationship between plasma concentrations and pharmacological effects of labetalol. Eur J Clin Pharmacol (1977) 1.71
Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol. Br J Clin Pharmacol (1976) 1.53
Routine programmed electrical stimulation in survivors of acute myocardial infarction for prediction of spontaneous ventricular tachyarrhythmias during follow-up: results, optimal stimulation protocol and cost-effective screening. J Am Coll Cardiol (1991) 1.49
Ranitidine--a new H2-receptor antagonist. Gut (1980) 1.47
The dilemma of the prolonged QT interval in early drug studies. Br J Clin Pharmacol (1996) 1.45
Skill mix between nurses and doctors working in primary care-delegation or allocation: a review of the literature. Int J Nurs Stud (2000) 1.42
Dimensions of the human posterior septal space and coronary sinus. Am J Cardiol (1991) 1.40
Heat exhaustion in The Sun-Herald City to Surf fun run. Med J Aust (1994) 1.38
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol (2012) 1.34
Double-blind trial of labetalol. Br J Clin Pharmacol (1976) 1.22
Construction and preliminary characterization of the rat casein and alpha-lactalbumin cDNA clones. J Biol Chem (1981) 1.18
Effects of labetalol and propranolol on histamine-induced bronchoconstriction in normal subjects. Br J Clin Pharmacol (1977) 1.17
Ventricular electrical instability: a predictor of death after myocardial infarction. Am J Cardiol (1983) 1.17
Multihormonal regulation of casein gene expression at the transcriptional and posttransciptional levels in the mammary gland. Recent Prog Horm Res (1980) 1.10
Clinical pharmacology of labetalol. Br J Clin Pharmacol (1979) 1.09
Adrenoceptor blockade of the circulatory responses to intravenous isoproterenol. Clin Pharmacol Ther (1978) 1.08
Pharmacological basis for antihypertensive effects of intravenous labetalol. Br Heart J (1977) 1.08
Cortical-area specific block of genetically determined absence seizures by ethosuximide. Neuroscience (2004) 1.08
Curative surgery for atrioventricular junctional ("AV nodal") reentrant tachycardia. J Am Coll Cardiol (1985) 1.07
Labetalol and urinary catecholamines. Br Med J (1978) 1.05
Modification of pressor responses induced by 'cold' [proceedings]. Br J Clin Pharmacol (1977) 1.03
Extremely large variations of atmospheric 14C concentration during the last glacial period. Science (2001) 0.98
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol (2015) 0.97
Extracellular neurotransmitter changes in cerebral ischaemia. Cerebrovasc Brain Metab Rev (1995) 0.95
Side-effects of ranitidine. Lancet (1982) 0.95
Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. Cancer J (2009) 0.94
Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer. Clin Oncol (R Coll Radiol) (2009) 0.93
Circulatory effects of noradrenaline and adrenaline before and after labetalol. Br J Clin Pharmacol (1979) 0.93
Restriction enzyme mapping and heteroduplex analysis of the rat milk protein cDNA clones. J Biol Chem (1981) 0.92
Electrophysiologic substrate for ventricular tachycardia: correlation of properties in vivo and in vitro. Circulation (1984) 0.92
Extracellular N-acetylaspartate in the rat brain: in vivo determination of basal levels and changes evoked by high K+. J Neurochem (1994) 0.92
Circulatory and alpha-adrenoceptor blocking effects of phentolamine. Br J Clin Pharmacol (1978) 0.91
The effects of oral AH 5158, a combined α and β-adrenoceptor antagonist, in healthy volunteers. Br J Clin Pharmacol (1974) 0.91
A controlled trial in travellers' diarrhoea. Practitioner (1970) 0.90
Effects of H1- and H2-receptor blocking agents on histamine-induced bronchoconstriction in non-asthmatic subjects. Br J Clin Pharmacol (1979) 0.89
Prophylactic value of clioquinol against travellers' diarrhoea. Lancet (1971) 0.89
Rate of onset of hypotensive response with oral labetalol [proceedings]. Br J Clin Pharmacol (1977) 0.87
Value of programmed stimulation and exercise testing in predicting one-year mortality after acute myocardial infarction. Am J Cardiol (1985) 0.87
Labetalol and urinary catecholamines. Br Med J (1979) 0.86
Concurrent antagonism of isoproterenol and norepinephrine after labetalol. Clin Pharmacol Ther (1978) 0.86
Does the induction of ventricular flutter or fibrillation at electrophysiologic testing after myocardial infarction have any prognostic significance? Am J Cardiol (1995) 0.85
A new protocol of programmed stimulation for assessment of predisposition to spontaneous ventricular arrhythmias. Eur Heart J (1983) 0.85
Indomethacin-associated peptic ulceration. N Z Med J (1978) 0.84
Blood pressure reduction by incremental infusion of labetalol in patients with severe hypertension. Br J Clin Pharmacol (1979) 0.84
Dimensions of the triangle of Koch in humans. Am J Cardiol (1992) 0.83
N-methyl-D-aspartate receptors modulate extracellular 5-hydroxytryptamine concentration in rat hippocampus and striatum in vivo. Neurosci Lett (1994) 0.82
Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. J Clin Gastroenterol (1983) 0.82
Time course of changes in extracellular lactate evoked by transient K(+)-induced depolarisation in the rat striatum. J Neurochem (1994) 0.81
Electrophysiological and anatomic differences between canine hearts with inducible ventricular tachycardia and fibrillation associated with chronic myocardial infarction. Circ Res (1989) 0.81
Lowered skin blood flow and erythrocyte sphering in collapsed fun-runners. Lancet (1986) 0.80
Comparison of energy metabolism in liver grafts from donors after circulatory death and donors after brain death during cold storage and reperfusion. Br J Surg (2014) 0.80
Hypoosmolarity induces an increase of extracellular N-acetylaspartate concentration in the rat striatum. Neurochem Res (1998) 0.80
Differences between patients with ventricular tachycardia and ventricular fibrillation as assessed by signal-averaged electrocardiogram, radionuclide ventriculography and cardiac mapping. J Am Coll Cardiol (1988) 0.80
Effects of 5-fluorouracil treatment on rat liver microsomal enzymes. Xenobiotica (1995) 0.80
Reduction in incidence of inducible ventricular tachycardia after myocardial infarction by treatment with streptokinase during infarct evolution. J Am Coll Cardiol (1990) 0.80
Neuroprotective efficacy of AR-A008055, a clomethiazole analogue, in a global model of acute ischaemic stroke and its effect on ischaemia-induced glutamate and GABA efflux in vitro. Neuropharmacology (2001) 0.80
Patients with two types of atrioventricular junctional (AV nodal) reentrant tachycardia. Evidence that a common pathway of nodal tissue is not present above the reentrant circuit. Circulation (1991) 0.79
Self-poisoning with beta-blockers. Br Med J (1978) 0.79
Combined intracerebral microdialysis and electrophysiological recording: methodology and applications. J Neurosci Methods (1993) 0.79
Comparison of immediate versus day to day variability of ventricular tachycardia induction by programmed stimulation. J Am Coll Cardiol (1989) 0.79
Technique for maximizing the frequency response of the signal averaged Frank vectorcardiogram. J Biomed Eng (1986) 0.79
Electrophysiologic studies in patients with unexplained syncope. Int J Cardiol (1992) 0.78
Extrastimulus-related shortening of the first postpacing interval in digitalis-induced ventricular tachycardia: observations during programmed electrical stimulation in the conscious dog. J Am Coll Cardiol (1983) 0.78
The prognostic significance of programmed ventricular stimulation after myocardial infarction: a review. Circulation (1987) 0.78
Comparison of labetalol with other anti-hypertensive drugs. Br J Clin Pharmacol (1982) 0.78
Infrared thermometry in the diagnosis and treatment of heat exhaustion. Int J Sports Med (1996) 0.78
Extracellular neuroactive amino acids in the rat striatum during ischaemia: comparison between penumbral conditions and ischaemia with sustained anoxic depolarisation. J Neurochem (1993) 0.78
Changes in ventricular activation time on the signal-averaged electrocardiogram in the first year after acute myocardial infarction. Am J Cardiol (1987) 0.78
Monolithic column-based reversed-phase liquid chromatography separation for amino acid assay in microdialysates and cerebral spinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.78
Effect of excision of ventricular myocardium on delayed potentials detected by the signal-averaged electrocardiogram in patients with ventricular tachycardia. Am J Cardiol (1987) 0.77
Simultaneous mapping of the tricuspid and mitral valve annuli at electrophysiological study. Br Heart J (1995) 0.77
Measurement of plasma and urine amino acids by high-performance liquid chromatography with electrochemical detection using phenylisothiocyanate derivatization. J Chromatogr (1990) 0.77
Accuracy of various methods of localization of the orifice of the coronary sinus at electrophysiologic study. Am J Cardiol (1992) 0.77
Quantitation of day to day variability in mode of induction of ventricular tachyarrhythmias by programmed stimulation. J Am Coll Cardiol (1988) 0.77
Disposition of salmeterol xinafoate in laboratory animals and humans. Drug Metab Dispos (1994) 0.77
Beta-blockers in treatment of hypertension. Br Med J (1978) 0.76
Surgical therapy for supraventricular tachycardia, a potentially curable disorder. J Thorac Cardiovasc Surg (1987) 0.76
Plasma concentrations of salbutamol after an oral slow-release preparation. Curr Med Res Opin (1983) 0.76
Use of high-performance liquid chromatography to study the caeruloplasmin-catalysed oxidation of biogenic amines. I. Single substrate systems. J Chromatogr (1983) 0.76
Sympathomimetic amine infusion after beta-adrenoceptor and parasympathetic blockade [proceedings]. Br J Clin Pharmacol (1979) 0.76
Ranitidine--pharmacology and clinical use. J Clin Hosp Pharm (1983) 0.76
Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium. Br J Clin Pharmacol (1979) 0.75
Deaths in a heat wave. Aust N Z J Med (1995) 0.75